β-Blockers in the management of hypertension in patients with type 2 diabetes mellitus: Is there a role?

Drugs

Volumn 61, Issue 4, 2001, Pages 429-435

  Dunne, Fidelma ^a   Kendall, Martin J ^a   Martin, Una ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELIPROLOL; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; OXPRENOLOL; PINDOLOL; PROPRANOLOL; TIMOLOL;

ALPHA ADRENERGIC RECEPTOR BLOCKING; DEATH; DIABETIC RETINOPATHY; DRUG SELECTIVITY; HEART FAILURE; HUMAN; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPOPHILICITY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; REVIEW; STROKE;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION;

EID: 0035059370     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161040-00001     Document Type: Review

References (71)

1. The rising global burden of diabetes and its complications; estimates and projections to the year 2010
2. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians
3. Role of obesity and fat distribution in non-insulin-dependent diabetes mellitus in Mexican Americans and non-Hispanic whites
4. Dietry fat predicts conversion from impaired glucose tolerance to NIDDM. The Sun Luis Valley Diabetes Study
5. Physical activity and reduced occurrence of non-insulin dependent diabetes mellitus
6. Diabetes, other risk factors, and 12 yr cardiovascular mortality in men screened in the multiple risk factor intervention trial
7. End stage renal disease attributable to diabetes mellitus
8. UKPDS Study 23: Risk factors for coronary artery disease in non-insulin dependent diabetes
9. UK prospective Diabetes Study X: Urinary albumin excretion over 3 years in diet-treated type 2 diabetic patients, and association with hypertension, hyperglycaemia, and hypertriglyceridaemia
10. UK Prospective Diabetes Study 30: Diabetic retinopathy at diagnosis of type 2 diabetes and associated risk factors
11. HDS 1: Prevalence of hypertension in newly presenting type 2 diabetic patients, the association with risk factors for cardio-vascular and diabetic complications
12. Hyperlipidaemia in diabetes
13. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes
14. Lipoprotein subspecies and risk of coronary disease
15. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications
16. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM
17. Age-independent oxidative stress in elderly patients with non-insulin dependent diabetes mellitus (NIDDM)
18. Atherosclerosis or lipoprotein-induced endothelial dysfunction: Potential mechanisms underlying reduction in EDRF/nitric oxide activity
19. Dyslipoproteinaemia and hyperoxidarive stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus
20. Diabetic dyslipidaemia and coronary heart disease: New perspectives
21. Epidemiology of cardiovascular complications of diabetes
22. Differences in biological risk factors for cardiovascular disease between three ethnic groups in the Whitehall 11 study
23. Prevalence detection and management of cardiovascular risk factors in different ethnic groups in South London
24. Special considerations in the therapy of diabetic hypertension
25. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease
26. MRC Trial of treatment of hypertension in older adults: Principal results
27. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes
28. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes
29. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes
30. Are selective β adrenoceptor blocking agents an advantage?
31. Treating the diabetic patient with coronary disease
32. Effect of -blockade on mortality among high-risk and low-risk patients after myocardial infarction
33. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
34. Diabetes as a risk factor for myocardial infarction: Population and gender perspectives
35. Diabetes as a risk factor for sudden death
36. Usefulness of β-blocker therapy in patients with non-insulin dependent diabetes mellims and coronary artery disease
37. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
38. A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results
39. βBlockers and sudden cardiac death
40. The role of β receptor blockade in preventing sudden death
41. Heart rate as a therapeutic target in heart failure
42. Importance of heart rate in determining β-blocker efficacy in acute and long-term acute myocardial infarction intervention trials
43. Heart rate as a target for the prevention of sudden death
44. β-blockade after myocardial infarction: Systematic review and meta regression analysis
45. Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials
46. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
47. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
48. Carvedilol
49. Implications of discontinuation of doxazosin arm of ALLHAT
50. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone
51. Nebivolol vasodilates human forearm vasculature: Evidence for an L-Arginine/NO dependent mechanism
52. Pharmacological and haemodynamic profile of nebivolol, a chemically novel, potent, and selective B-adrenergic antagonist
53. Clinical pharmacology of nebivolol
54. The impact of ethnicity on response to antihypertensive therapy
55. The choice of anti-hypertensive therapy in the diabetic patient
56. Antihypertensive treatment and plasma lipoprotein levels: The associations in data from a population study
57. β-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus
58. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
59. β-locker effects on plasma lipids during prolonged treatment of hypertensive patients with hypemholesterolaemia
60. Effects of antihypertensive drugs on coronary artery disease risk: A meta-analysis
61. Lipids and lipoproteins during antihypertensive drug therapy: Comparison of doxazosin and atenolol in a randomised, double-blind trial: The Alpha Canada Study
62. Effects of lisonopril and bisoprolol on lipoprotein metabolism in patients with mild-to-moderate essential hypertension
63. Results of therapy with carvedolol, a β-blocker vasodilator with antioxidant properties, in hypertensive patients
64. A double-blind comparison of the effects of carvedolol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension
65. Treating hypertension in black compared with white non-insulin dependent diabetics: A double blind trial of verapamil and metoprolol
66. β-Blockers in hypertensive non-insulin dependent diabetes: Comparison between penbutolol and propranolol on metabolic control and response to insulin-induced hypoglycaemia
67. Effect of cardioselective and non-selective β-blockade on the hypoglycaemic response to insulin-dependent diabetics
68. β-Blockers for the treatment of hypertension in patients with diabetes: Exploring the contraindication myth
69. Association between antihypertensive drug use and hypoglycaemia: A case-control study of diabetic users of insulin or sulfonylureas
70. Drug treatment of hypertension complicating diabetes mellitus